Syner-G

JULY 7, 2023

Future growth will be driven by factors that include payers mandating the use of such diagnostics, increased understanding of drug safety, advancements in quality of diagnostic testing, and more informed and proactive consumers. Efficient clinical and commercial manufacturing presents issues, too.

Medical Records 52

Medical Records Drug Development Dosage 52

Pharmacy Is Right For Me

APRIL 4, 2023

There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! Another unique aspect of this model is that all interprofessional team members can access and document within a universal electronic medical record (EPIC).

Hospitals 130

Hospitals Communication Medical Records Dosage 130

FDA Law Blog: Biosimilars

OCTOBER 2, 2023

Two weeks ago, FDA published a draft of its latest drug development guidance explaining how drug and biological product developers can use this pathway to meet the statutory standard for efficacy. The guidance’s second warning reminds drug developers that FDA regulations (i.e.,

Drug Development 64

Drug Development Documentation Labelling Medical Records 64

Viseven

DECEMBER 19, 2022

That is why RWE serves many uses and presents many advantages across healthcare ecosystems. Operating with real-world evidence essentially affects the base for medication approvals and drug development acceleration. Why Is Real-World Evidence Important? Big Pharma has already benefited from it.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Medical Records Diabetes 52

Pharmaceutical Technology

APRIL 24, 2023

Artificial intelligence (AI) is set to be the most disruptive emerging technology in drug development in 2023, unlocking advanced analytics, enabling automation, and increasing speed across the clinical trial value chain. Once the trial is launched, you can use AI to do automatic querying and medical coding,” says Clark.

Documentation 52

Documentation Medical Records Communication Drug Development 52

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

The Draft Guidance emphasizes that study team should not answer the questions based on observation or even on existing medical records. Instead, the information should be self-reported or, if that is not possible, provided by a first-degree relative or knowledgeable representative.

Medical Records 59

Medical Records Drug Development 59